Estados financieros detallados de Reviva Pharmaceuticals Holdings, Inc. (RVPH): cuenta de resultados, balance general y flujo de caja. Sigue la evolución de márgenes, deuda, liquidez y rentabilidad año a año con hasta 20 años de histórico.
Resumen del Análisis
Márgenes de los últimos 12 meses: margen bruto 0.0%, margen operativo 0.0%, margen neto 0.0%.
Al precio actual de $0.49, RVPH presenta beneficios negativos (P/E no significativo) y un ROE del -64.39%. La capitalización bursátil es de $6M.
Cuenta de Resultados (10 años)
| Año | 2019 | 2020 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Ingresos | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Coste de Ventas | 0 | 0 | $724740 | 0 | 0 | 0 | 0 | 0 |
| Beneficio Bruto | 0 | 0 | -$724740 | 0 | 0 | 0 | 0 | 0 |
| I+D | $946301 | $195744 | $295150 | $4.9M | $18.9M | $31.4M | $22.9M | $11.7M |
| Generales y Administrativos | $175579 | $181116 | $2.1M | $5.3M | $5.4M | $8.1M | $7.9M | $8.5M |
| Gastos Operativos | $1.1M | $376860 | $2.4M | $10.1M | $24.3M | $39.5M | $30.8M | $20.2M |
| Beneficio Operativo | -$1.1M | -$376860 | -$2.4M | -$10.1M | -$24.3M | -$39.5M | -$30.8M | -$20.2M |
| EBITDA | -$1.1M | -$376014 | -$2.3M | -$10.1M | -$24.1M | -$39.2M | -$29.9M | -$19.8M |
| Gastos por Intereses | $557675 | $469373 | $1.5M | $2414 | $182802 | $33725 | $18497 | $13402 |
| Beneficio Antes de Impuestos | -$1.7M | -$846032 | -$3.8M | -$8.5M | -$24.3M | -$39.2M | -$29.9M | -$19.8M |
| Impuestos | $800 | $800 | $800 | $6004 | $20777 | $16949 | $19514 | $18889 |
| Beneficio Neto | -$1.7M | -$846832 | -$3.8M | -$8.5M | -$24.3M | -$39.3M | -$29.9M | -$19.9M |
| BPA | $-16.48 | $-6.20 | $-24.80 | $-11.60 | $-29.00 | $-33.00 | $-18.00 | $-5.48 |
| BPA Diluido | $-16.48 | $-6.20 | $-24.80 | $-11.60 | $-29.00 | $-33.00 | $-18.00 | $-5.48 |
| Acciones en Circulación (Diluidas) | $101984 | $138531 | $153084 | $739542 | $975824 | $1.2M | $1.7M | $3.6M |
Balance (10 años)
| Año | 2019 | 2020 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Caja y Equivalentes | 0 | $193 | $8.8M | $29.7M | $18.5M | $23.4M | $13.5M | $14.4M |
| Inversiones a Corto | $65.2M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cuentas por Cobrar | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Inventario | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Activos Corrientes | $65.2M | $193 | $8.8M | $31.4M | $18.9M | $23.7M | $14.7M | $15.1M |
| Inmovilizado Material | 0 | $591 | 0 | 0 | 0 | 0 | 0 | 0 |
| Fondo de Comercio | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Activos Intangibles | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Activos Totales | $65.2M | $2600 | $8.8M | $31.4M | $18.9M | $23.7M | $15.5M | $15.9M |
| Cuentas por Pagar | 0 | $224543 | $1.0M | $509583 | $3.5M | $3.8M | $6.3M | $3.0M |
| Deuda a Corto | 0 | $3.8M | 0 | 0 | 0 | 0 | $458154 | $406875 |
| Pasivos Corrientes | 0 | $100102 | $1.3M | $2.3M | $10.0M | $17.2M | $14.6M | $7.3M |
| Deuda a Largo | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Pasivos Totales | $6.1M | $6.8M | $3.3M | $2.7M | $10.5M | $18.0M | $14.7M | $7.3M |
| Reservas | 0 | -$54.5M | -$58.3M | -$66.8M | -$95.1M | -$134.4M | -$164.3M | -$184.1M |
| Patrimonio Neto | 0 | -$6.8M | $5.5M | $28.7M | $8.4M | $5.7M | $812572 | $8.6M |
| Deuda Total | 0 | $3.8M | 0 | 0 | 0 | 0 | $458154 | $406875 |
| Deuda Neta | -$65.2M | $3.8M | -$8.8M | -$29.7M | -$18.5M | -$23.4M | -$13.0M | -$14.0M |
| Capital Circulante | $65.2M | -$99909 | $7.4M | $29.1M | $9.0M | $6.5M | $81861 | $7.8M |
Flujo de Caja (10 años)
| Año | 2019 | 2020 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Beneficio Neto | -$1.7M | -$846832 | -$3.8M | -$8.5M | -$24.3M | -$39.3M | -$29.9M | -$19.9M |
| Amortizaciones | $17718 | $645 | $591 | 0 | 0 | 0 | 0 | 0 |
| Compensación en Acciones | $21054 | 0 | 0 | $106713 | $176735 | $3.4M | $1.6M | $2.2M |
| Cambio en Capital Circulante | $541979 | $634152 | -$2.3M | -$702173 | $8.9M | $7.3M | -$4.5M | -$6.9M |
| Flujo de Caja Operativo | -$1.1M | -$218444 | -$4.1M | -$10.7M | -$19.0M | -$28.3M | -$33.5M | -$24.6M |
| Inversiones (CapEx) | 0 | 0 | 0 | 0 | 0 | $3 | -$4 | 0 |
| Adquisiciones | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Recompra de Acciones | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividendos Pagados | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Flujo de Caja Libre | -$1.1M | -$218444 | -$4.1M | -$10.7M | -$19.0M | -$28.3M | -$33.5M | -$24.6M |
Crecimiento y Márgenes (10 años)
| Año | 2019 | 2020 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Crecimiento Beneficio Neto (anual) | +49.6% | -346.8% | -125.2% | -185.6% | -61.3% | +23.8% | +33.6% | |
| Crecimiento BPA (anual) | +62.4% | -300.0% | +53.2% | -150.0% | -13.8% | +45.5% | +69.6% | |
| Cambio en Acciones (anual) | +35.8% | +10.5% | +383.1% | +31.9% | +21.9% | +39.3% | +118.9% | |
| Crecimiento FCF (anual) | +79.6% | -1761.6% | -162.3% | -77.7% | -49.4% | -18.4% | +26.7% | |
| Tasa Impositiva Efectiva | -0.0% | -0.1% | -0.0% | -0.1% | -0.1% | -0.0% | -0.1% | -0.1% |
Datos por Acción (10 años)
| Año | 2019 | 2020 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| FCF por Acción | $-10.51 | $-1.58 | $-26.56 | $-14.43 | $-19.43 | $-23.80 | $-20.24 | $-6.78 |
| Dividendo por Acción | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Acciones en Circulación (Básicas) | $101984 | $138531 | $153084 | $739542 | $975824 | $1.2M | $1.7M | $3.6M |
Qué mirar en Biotech
La mayoría de biotechs pequeñas pierden dinero. Analizarlas con P/E no tiene sentido — mira caja y pipeline.
- Cash Runway — Meses de caja al ritmo de gasto actual. <18 meses = riesgo de dilución urgente
- Cash burn anual — Ritmo al que queman caja operativa. Comparar con posición de caja para proyectar runway
- Total Debt — Biotech sin ingresos + deuda = receta para bancarrota
- I+D / Capitalización — Cuánto invierten en pipeline vs lo que vale la empresa — indicador de intensidad investigadora
- Market cap / Cash — Si cotiza cerca de su caja, el mercado le da ~0 valor al pipeline — puede ser oportunidad o trampa
Rentabilidad
| Rentabilidad sobre capital | -64.39% |
| Rentabilidad sobre capital invertido | -17.05% |
| Rentabilidad sobre activos | -11.58% |
| Margen bruto | 0.00% |
| Margen operativo | 0.00% |
| Margen neto | 0.00% |
Salud financiera
| Deuda / Patrimonio | 0.01 |
| Ratio corriente | 3.56 |
| Piotroski F-Score | 2 |
| Altman Z-Score | -18.12 |
Ratios Clave (10 años)
| Año | 2019 | 2020 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| P/E | -12.21 | -34.06 | -7.05 | -4.98 | -2.93 | -3.12 | -2.01 | -1.02 |
| P/VC | 0.00 | -4.30 | 4.90 | 1.49 | 9.88 | 21.43 | 73.84 | 2.34 |
| P/V | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Margen Bruto | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Margen Operativo | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Margen Neto | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Empresas relacionadas: ANVS · ATNM · BCAB · BTAI · CELU · EVAX · FGEN
Explorar sector: Healthcare · Biotechnology
Más secciones de RVPH: Resumen · Valoración · Estadísticas · Estimaciones · Técnico · Propiedad · Noticias · Eventos
Descubre más: Radar — señales de acciones infravaloradas · Academia de Inversión — aprende a analizar acciones